STEMI 后低密度脂蛋白胆固醇水平与新动脉粥样硬化:CONNECT 随机临床试验的二次分析
该研究为 CONNECT 随机临床试验的事后分析,纳入 178 例于直接 PCI 后 3 年接受 OCT 检查的 STEMI 患者,比较达标与未达标指南推荐 LDL-C 水平者的新动脉粥样硬化患病率。
要点
- STEMI 患者 DES 置入后 3 年,达标 LDL-C 者新动脉粥样硬化患病率低于未达标者。
- 未达指南推荐 LDL-C 目标者新动脉粥样硬化风险比为 3.00(95%CI 1.19-8.24,P=0.02)。
核心结论
- 治疗中 LDL-C 水平是 STEMI 患者 DES 置入后 3 年新动脉粥样硬化的独立预测因素。
- 达标指南推荐 LDL-C 水平者新动脉粥样硬化患病率更低,强调降 LDL-C 对预防新动脉粥样硬化形成的重要性。
研究设计与样本
- CONNECT 随机临床试验的事后分析,在瑞士和日本 7 个中心随机纳入 239 例 STEMI 患者,比较生物可降解聚合物与耐久聚合物依维莫司洗脱支架 PCI。
- 178 例患者在直接 PCI 后 3 年接受 OCT 评估新动脉粥样硬化患病率,按是否达标指南推荐 LDL-C 水平分组比较。
- 事后分析数据分析时间为 2024 年 9 月至 2025 年 10 月。
主要发现
- 178 例接受 OCT 的患者平均(SD)年龄 63.4(10.9)岁,女性 27 例(15%)。
- 98 例(55%)达标指南推荐 LDL-C 水平,80 例(45%)未达标,两组平均(SD)治疗中 LDL-C 分别为 48(13)与 87(37)mg/dL。
- 达标组新动脉粥样硬化患病率低于未达标组(7 例[7%] vs 15 例[19%];未达标者 OR 3.00,95%CI 1.19-8.24,P=0.02)。
关键数值与推荐
- 指南推荐的治疗中 LDL-C 目标水平,达标组平均(SD)为 48(13)mg/dL,未达标组为 87(37)mg/dL。
- 新动脉粥样硬化患病率达标组 7%、未达标组 19%,未达标者 OR 3.00(95%CI 1.19-8.24,P=0.02)。
临床怎么用
- STEMI 患者 DES 置入后应积极降 LDL-C 至指南推荐目标,以降低远期新动脉粥样硬化形成风险。
- 治疗中 LDL-C 水平可作为 DES 置入后新动脉粥样硬化风险的独立预测指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neoatherosclerosis represents a major cause of late stent failure and results in cardiac events after drug-eluting stent (DES) implantation. Achieving secondary preventive low-density lipoprotein cholesterol (LDL-C) target levels can reduce plaque progression in native coronary arteries; however, its association with neoatherosclerosis formation remains unclear. OBJECTIVE: To determine whether achieving guideline-endorsed LDL-C levels after DES implantation is associated with reduced risk of long-term neoatherosclerosis formation. DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc analysis of the CONNECT randomized clinical trial conducted at 7 sites in Switzerland and Japan that had randomized 239 patients with ST-segment elevation myocardial infarction (STEMI) to percutaneous coronary intervention (PCI) with biodegradable- or durable-polymer everolimus-eluting stents between June 2017 and June 2020. The prevalence of neoatherosclerosis was assessed with optical coherence tomography (OCT) 3 years after primary PCI. Data analysis for this post hoc analysis was conducted from September 2024 to October 2025. INTERVENTION: Patients with STEMI received primary PCI with DES, and statin therapy was recommended according to country-specific guidelines. MAIN OUTCOMES AND MEASURES: The prevalence of neoatherosclerosis 3 years after primary PCI was compared between patients with vs without achievement of guideline-endorsed target LDL-C levels. A multivariable predictor analysis was performed to determine whether on-treatment LDL-C levels were associated with occurrence of neoatherosclerosis. RESULTS: Among 178 patients (mean [SD] age, 63.4 [10.9] years; 27 [15%] female) who underwent OCT at 3 years, 98 patients (55%) achieved the target LDL-C level and 80 patients (45%) did not. The mean (SD) on-treatment LDL-C levels for these groups were 48 (13) and 87 (37) mg/dL, respectively (to convert to millimoles per liter, multiply by 0.0259). The prevalence of neoatherosclerosis was lower in patients who achieved the target LDL-C level as compared with patients who did not (7 patients [7%] vs 15 patients [19%], respectively; odds ratio for those who did not achieve the LDL-C target level, 3.00; 95% CI, 1.19-8.24; P = .02). On-treatment LDL-C level (per 25-mg/dL increase) emerged as an independent determinant of neoatherosclerosis at 3 years in multivariable logistic regression analysis (odds ratio, 1.46; 95% CI, 1.09-2.01; P = .01). CONCLUSIONS AND RELEVANCE: On-treatment LDL-C level emerged as an independent predictor of neoatherosclerosis 3 years after DES implantation for STEMI. Neoatherosclerosis was less frequent among patients who achieved the guideline-recommended on-treatment LDL-C level, underscoring the importance of LDL-C lowering in preventing neoatherosclerosis formation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03440801.
引用
- Häner JD, Kakizaki R, Taniwaki M, et al. Low-Density Lipoprotein Cholesterol Levels and Neoatherosclerosis After STEMI: A Secondary Analysis of the CONNECT Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41405905. doi:10.1001/jamacardio.2025.4723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。